The analysts are projecting a net loss of between 8 to 10 cents a share. I think that gross biosurgery sales could come in around 4.2 to 4.6 million resulting in a net loss of between 4 to 6 cents. This is my conservative estimate. If the net loss is in fact at or near my estimate, I expect the stock to surge Tuesday morning. Next quarter will be breakeven or better.
bio surgery revs last quarter 2.9 million. Q to Q of 30% rev increase shows a bit less than a million dollars increase for this quarter. My number is 3.9 million. That is the information from the company itself.